170 related articles for article (PubMed ID: 32404523)
21. A first-in-human study of the novel HIV-fusion inhibitor C34-PEG
Quinn K; Traboni C; Penchala SD; Bouliotis G; Doyle N; Libri V; Khoo S; Ashby D; Weber J; Nicosia A; Cortese R; Pessi A; Winston A
Sci Rep; 2017 Aug; 7(1):9447. PubMed ID: 28842581
[TBL] [Abstract][Full Text] [Related]
22. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.
Chong H; Xue J; Zhu Y; Cong Z; Chen T; Wei Q; Qin C; He Y
PLoS Pathog; 2019 Feb; 15(2):e1007552. PubMed ID: 30716118
[TBL] [Abstract][Full Text] [Related]
23. Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
Huet T; Kerbarh O; Schols D; Clayette P; Gauchet C; Dubreucq G; Vincent L; Bompais H; Mazinghien R; Querolle O; Salvador A; Lemoine J; Lucidi B; Balzarini J; Petitou M
Antimicrob Agents Chemother; 2010 Jan; 54(1):134-42. PubMed ID: 19805567
[TBL] [Abstract][Full Text] [Related]
24. Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.
Wu Y; Xue J; Wang C; Li W; Wang L; Chen W; Prabakaran P; Kong D; Jin Y; Hu D; Wang Y; Lei C; Yu D; Tu C; Bardhi A; Sidorov I; Ma L; Goldstein H; Qin C; Lu L; Jiang S; Dimitrov DS; Ying T
J Virol; 2019 Oct; 93(20):. PubMed ID: 31375583
[TBL] [Abstract][Full Text] [Related]
25. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
26. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
27. Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.
Etemad-Moghadam B; Rhone D; Steenbeke T; Sun Y; Manola J; Gelman R; Fanton JW; Racz P; Tenner-Racz K; Axthelm MK; Letvin NL; Sodroski J
J Virol; 2001 Jun; 75(12):5646-55. PubMed ID: 11356972
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans.
Sharda N; Khandelwal P; Zhang L; Caceres-Cortes J; Marathe P; Chimalakonda A
Eur J Pharm Sci; 2021 Oct; 165():105928. PubMed ID: 34265405
[TBL] [Abstract][Full Text] [Related]
29. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
[TBL] [Abstract][Full Text] [Related]
30. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
[TBL] [Abstract][Full Text] [Related]
31. An HIV-1 infection-related idiotype/clonotype (1F7) is expressed on antibodies directed to envelope glycoprotein in simian immunodeficiency virus- and chimeric simian/human immunodeficiency virus-infected rhesus monkeys.
Müller S; Margolin DH; Min G
Hybridoma; 1997 Feb; 16(1):17-21. PubMed ID: 9085123
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.
Mould DR; Zhang X; Nieforth K; Salgo M; Buss N; Patel IH
Clin Pharmacol Ther; 2005 Jun; 77(6):515-28. PubMed ID: 15961983
[TBL] [Abstract][Full Text] [Related]
33. Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in simian/human immunodeficiency virus-infected and vaccinated rhesus monkeys detected using a peptide-major histocompatibility complex class II tetramer.
Kuroda MJ; Schmitz JE; Lekutis C; Nickerson CE; Lifton MA; Franchini G; Harouse JM; Cheng-Mayer C; Letvin NL
J Virol; 2000 Sep; 74(18):8751-6. PubMed ID: 10954578
[TBL] [Abstract][Full Text] [Related]
34. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
[TBL] [Abstract][Full Text] [Related]
35. In situ depot formation of anti-HIV fusion-inhibitor peptide in recombinant protein polymer hydrogel.
Asai D; Kanamoto T; Takenaga M; Nakashima H
Acta Biomater; 2017 Dec; 64():116-125. PubMed ID: 29037895
[TBL] [Abstract][Full Text] [Related]
36. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C.
Tartaglia LJ; Gupte S; Pastores KC; Trott S; Abbink P; Mercado NB; Li Z; Liu PT; Borducchi EN; Chandrashekar A; Bondzie EA; Hamza V; Kordana N; Mahrokhian S; Lavine CL; Seaman MS; Li H; Shaw GM; Barouch DH
J Virol; 2020 May; 94(10):. PubMed ID: 32132241
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
38. Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.
Danial M; van Dulmen TH; Aleksandrowicz J; Pötgens AJ; Klok HA
Bioconjug Chem; 2012 Aug; 23(8):1648-60. PubMed ID: 22770564
[TBL] [Abstract][Full Text] [Related]
39. [The current progress in the development of HIV-1 fusion inhibitors].
Shi WG; Jia QY; Liu KL
Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
[TBL] [Abstract][Full Text] [Related]
40. Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.
Palesch D; Bosinger SE; Mavigner M; Billingsley JM; Mattingly C; Carnathan DG; Paiardini M; Chahroudi A; Vanderford TH; Silvestri G
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
